Self‐esteem in remitted bipolar disorder patients: a meta‐analysis

Nilsson, Kristine Kahr; Jørgensen, Carsten René; Craig, Tom; Straarup, Krista Nielsen; Licht, Rasmus W

doi:10.1111/j.1399-5618.2010.00856.x

Cited by 42 publications

(38 citation statements)

References 65 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[33][34][35][36][37] Moreover, there is com- provided as an 8-session intervention 8-session intervention MBSR = mindfulness-based stress reduction, MBCT = mindfulness-based cognitive therapy pelling evidence that processing of self-referent information is abnormal in affective illness. [38][39][40][41] Other research also suggests that an association exists between self-esteem and mood and anxiety disorders, including bipolar disorder, 39,42 generalized anxiety disorder, 43 obsessive-compulsive disorder, 44,45 PTSD, 46-48 social phobia, 49,50 and panic disorder. 51 Finally, the effectiveness of interventions targeting negative schemas through cognitive therapy for the treatment of mood disorders is well established.…”

Section: Psychological Mechanismsmentioning

confidence: 95%

Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, and Zen Meditation for Depression, Anxiety, Pain, and Psychological Distress

Marchand

2012

Journal of Psychiatric Practice

245

133

View full text Add to dashboard Cite

Section: Psychological Mechanismsmentioning

confidence: 95%

Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, and Zen Meditation for Depression, Anxiety, Pain, and Psychological Distress

Marchand

2012

Journal of Psychiatric Practice

245

133

View full text Add to dashboard Cite

“…A meta-analysis of data from 12 trials (n = 1838) found that the self-esteem of patients with remitted BD was significantly lower than that of controls but significantly higher than that of patients with remitted major depressive disorder (MDD) (12). In addition, self-esteem may follow a fluctuating course during remission of BD.…”

Section: Impactmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

et al. 2012

View full text Add to dashboard Cite

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.  Bipolar Disord 2012: 00: 000–000. © 2012 John Wiley & Sons A/S.Published by Blackwell Publishing Ltd.The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain largely unchanged. Lithium, valproate, and several atypical antipsychotic agents continue to be first‐line treatments for acute mania. Monotherapy with asenapine, paliperidone extended release (ER), and divalproex ER, as well as adjunctive asenapine, have been added as first‐line options.For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first‐line options. Lurasidone monotherapy and the combination of lurasidone or lamotrigine plus lithium or divalproex have been added as a second‐line options. Ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have been added as not‐recommended options for the treatment of bipolar depression. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long‐acting injection, and adjunctive ziprasidone continue to be first‐line options for maintenance treatment of bipolar disorder. Asenapine alone or as adjunctive therapy have been added as third‐line options.

show abstract

“…BD is associated with a greatly impaired quality of life, increased physical health burden (Vancampfort et al, 2016;Vancampfort et al, 2015) and disability (Hirschfeld et al, 2003;Yatham et al, 2004). Moreover, BD can impact employment (Reed et al, 2010) and lead to lower self-esteem (Nilsson et al, 2010) and reduced social interaction (Judd and Akiskal, 2003). Furthermore, approximately 23% of patients with BD report a history of suicide attempts (Kattimani et al, 2016) BD has a complicated, multifactorial etiology including genetic, neuro-endocrine, and environmental factors (Craddock and Sklar, 2013).…”

Section: Introductionmentioning

confidence: 99%

Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials

Tseng²,

Stubbs

et al. 2017

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

-keung Chow , Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Pnp(2017Pnp( ), doi: 10.1016Pnp( /j.pnpbp.2017 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.A C C E P T E D M A N U S C R I P T Aripiprazole was associated with lower relapse rates in bipolar mania when used in combination versus a placebo in maintenance therapy (odds ratio: 0.522, p<0.029). ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P TAripiprazole was also associated with higher levels of high density lipoprotein, lower dropout rates, but no difference in extrapyramidal symptoms in the maintenance phase versus a placebo or in comparison with other medications (haloperidol or lithium). Our results suggest that aripiprazole is effective and safe in treating bipolar mania. Further trials are necessary to evaluate the efficacy and tolerability versus other medications.

show abstract

Self‐esteem in remitted bipolar disorder patients: a meta‐analysis

Abstract: By revealing that BD patients do experience low self-esteem, the findings implicate a need for further understanding the causes and therapeutic impact of such abnormality in BD.

Cited by 42 publications

References 65 publications

Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, and Zen Meditation for Depression, Anxiety, Pain, and Psychological Distress

Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, and Zen Meditation for Depression, Anxiety, Pain, and Psychological Distress

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About